Since the parasite constantly changes its surface, it can avoid the immune defense of humans and invade the central nervous system, which leads to personality disturbances, sleep disruptions, and ultimately death. For patients affected by a severe T brucei infection in the central nervous system, there are no medicines that can treat both subspecies without incurring extremely serious side effects.
In a project directed by Professor Lars Thelander, scientists have previously discovered that the parasites' CTP synthetase, an enzyme responsible for the production of CTP-one of the four building blocks for mRNA synthesis, a process that is critical for the survival of the parasite-should be a key target for treating the disease.
In the current publication scientists have managed to show that the proper content of acivicin, a well-known cell toxin that has previously been used as a cancer drug, can inhibit the parasite's CTP synthetase, thereby permanently killing the trypanosomes in cell cultures. With daily doses of acivicin, trypanosome-infected mice have also been kept free of symptoms, as opposed to untreated mice that died within a few days.
"The advantage of acivicin is that it has already been used on humans. All the clinical studies have been performed, and we know that the drug can penetrate the central nervous system, which is not the case with many other medicines for trypanosomes. What's more, it can be taken in tablet form, which is extremely important in countries with limited health-care resources," says Artur Fijolek, co-author of the article.
The research team at the Umeå University Department of Medical Chemistry and Biophysics hopes soon to be able to find the appropriate dosage of acivicin that can permanently cure the infected mice.
"Expression, Purification, Characterization and in Vivo Targeting of Trypanosome CTP Synthetase for Treatment of African Sleeping Sickness," Artur Fijolek, Anders Hofer, and Lars Thelander. The Journal of Biological Chemistry, Vol. 282, No. 16. pp. 11858-11865, April 20, 2007.
For more information, please contact Artur Fijolek at e-mail firstname.lastname@example.org or phone: +46 (0)90-786 52 63 or Lars Thelander at e-mail email@example.com or phone: +46 (0)90-786 67 42.
Bertil Born | idw
The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences
Transforming plant cells from generalists to specialists
07.12.2016 | Duke University
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
07.12.2016 | Health and Medicine
07.12.2016 | Life Sciences
07.12.2016 | Health and Medicine